Evidence map›Paper›PMID 38414662›Full record

ArticleFrontiers in molecular biosciences2024

Pyrazinoic acid, the active form of the anti-tuberculosis drug pyrazinamide, and aromatic carboxylic acid analogs are protonophores.

Fabio L Fontes, Steven A Rooker, Jamie K Lynn-Barbe, Michael A Lyons, Debbie C Crans, Dean C Crick

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in molecular biosciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.6field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 7 citations in OpenAlex.

  1. TargetingACS omega · 2026
    Article
  2. Article
  3. Pyrazinamide killsbioRxiv : the preprint server for biology · 2025
    Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Fabio L FontesProgram in Cell and Molecular Biology, Colorado State University, Fort Collins, CO, United States.
Steven A RookerMycobacteria Research Laboratories, Department of Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, CO, United States.
Jamie K Lynn-BarbeMycobacteria Research Laboratories, Department of Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, CO, United States.
Michael A LyonsMycobacteria Research Laboratories, Department of Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, CO, United States.
Debbie C CransProgram in Cell and Molecular Biology, Colorado State University, Fort Collins, CO, United States.
Dean C CrickProgram in Cell and Molecular Biology, Colorado State University, Fort Collins, CO, United States.
Colorado State University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pyrazinoic acid is the active form of pyrazinamide, a first-line antibiotic used to treat

Indexed as

benzoic acidgrowth inhibitionMycobacterium tuberculosispara-aminosalicylic acidpicolinic acidQSARsalicylic aciduncoupling

Identifiers

PMID38414662
PMCPMC10896915
OpenAlexW4391783620

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.